Dr Reddy’s has completed the purchase of worldwide exclusive Intellectual Property Rights (IPR) for Fondaparinux sodium, its generic anti-coagulant drug, from Australian partner Alchemia for $17.5 million (around Rs 115 crore). Fondaparinux is a generic version of the anticoagulant drug Arixtra, which is approved in the US and Europe for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

(NDTV)